Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7823653 Monotherapy and in Combination With Faricimab in Diabetic Macular Edema
NCT07425522Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7823653 in diabetic macular edema (DME) (3 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Ocular Adverse Events (AEs) and Systemic AEs at 20 weeks. Started Apr 2026; status: recruiting.
02
Drugs
RO7823653
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07425522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425522.